Oncolytics Biotech is directing a broad clinical trial program with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes human trials using REOLYSIN® alone and in combination with chemotherapy or immune modulation, and delivered via local administration and/or intravenous administration. The Company's first pivotal trial will be a Phase III randomized clinical trial examining the intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-failed head and neck cancers.

Participation in Clinical Trials Using REOLYSIN®

REOLYSIN is available in a clinical trial setting only. It is not approved in any jurisdiction and not available for purchase. The Company does not participate in special access programs. Most of the trials are being conducted in the U.S. by Oncolytics and its clinical partners.

The Company and its employees have no influence over the inclusion of a patient in a clinical trial. To obtain a list of U.S. trials currently being conducted using REOLYSIN please visit www.clinicaltrials.gov and search using the term REOLYSIN. Each listing includes patient inclusion and exclusion criteria. If the patient’s physician determines that they might be a suitable trial candidate, they can contact a participating centre; there is contact information near the bottom of each trial listing.

While the Company does have a broad clinical program, it is increasingly focused on specific indications. Patients that cannot find a trial for their specific indication are invited to check the www.clinicaltrials.gov website periodically as the site is updated as new trials are announced.

Clinical Trial Chart

Click on clinical trial for more detailed information